VistaGen Therapeutics
VTGN
VTGN
116 hedge funds and large institutions have $168M invested in VistaGen Therapeutics in 2022 Q1 according to their latest regulatory filings, with 19 funds opening new positions, 30 increasing their positions, 37 reducing their positions, and 9 closing their positions.
New
Increased
Maintained
Reduced
Closed
more first-time investments, than exits
New positions opened: | Existing positions closed:
more funds holding
Funds holding: →
more funds holding in top 10
Funds holding in top 10: →
less ownership
Funds ownership: →
19% less repeat investments, than reductions
Existing positions increased: 30 | Existing positions reduced: 37
38% less capital invested
Capital invested by funds: $269M → $168M (-$101M)
92% less call options, than puts
Call options by funds: $41K | Put options by funds: $487K
Holders
116
Holding in Top 10
1
Calls
$41K
Puts
$487K
Top Buyers
| 1 | +$2.02M | |
| 2 | +$1.64M | |
| 3 | +$1.52M | |
| 4 |
Renaissance Technologies
New York
|
+$1.46M |
| 5 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
+$1.15M |
Top Sellers
| 1 | -$6.19M | |
| 2 | -$1.24M | |
| 3 | -$956K | |
| 4 |
GTC
Ghost Tree Capital
New York
|
-$849K |
| 5 |
SCM
Silverarc Capital Management
Boston,
Massachusetts
|
-$827K |